The effect of auranofin on granule protein secretion from neutrophils was investigated by a haemolytic plaque assay which can detect release of lactoferrin and myeloperoxidase from single adherent neutrophils. Lactoferrin secretion in response to N-formyl-methionylleucyl-phenylalanine (fMLP) was enhanced at low (0.25-1-0 ig/ml) and inhibited at high concentrations of auranofm (50% inhibition (ICso) at 3*7 .g/ml). A similar biphasic effect was also seen on degranulation mediated by granulocyte-macrophage colony stimulating factor (GM-CSF) (ICso 1-8 pg/mI). In contrast, exocytosis mediated by tumour necrosis factor was inhibited even at low concentrations of auranofin (ICso 0-6 pg/mI). Secretion induced by phorbol 12-myristate 13-acetate and A23187 was only inhibited at very high auranofin concentrations (ICso 10 and 8 /ml respectively). The effect of auranofin on myeloperoxidase secretion was also assessed and the IC50 values for the respective agents were as follows: tumour necrosis factor 0-7 pg/ml, fMLP 1-6 pg/ml, and phorbol myristate acetate 7-6 ig/ml. When neutrophils were preincubated -with auranofin (4 pg/mI) and then exposed to fMLP, tumour necrosis factor, or GM-CSF in the absence ofauranofm, lactoferrin release was enhanced if the preincubation time was short (one to three minutes) and inhibited when the time of preincubation was longer. It was concluded that auranofin, at concentrations achieved in the serum of patients, is a potent inhibitor of cytokine induced release of granule proteins from adherent neutrophils. This finding may be of clinical importance and shed light on the mechanism by which auranofin acts in rheumatoid arthritis.
then exposed to fMLP, tumour necrosis factor, or GM-CSF in the absence ofauranofm, lactoferrin release was enhanced if the preincubation time was short (one to three minutes) and inhibited when the time of preincubation was longer. It was concluded that auranofin, at concentrations achieved in the serum of patients, is a potent inhibitor of cytokine induced release of granule proteins from adherent neutrophils. This finding may be of clinical importance and shed light on the mechanism by which auranofin acts in rheumatoid arthritis. a lipophilic gold compound that has become widely used in the treatment of rheumatoid arthritis. The exact mode of action of auranofm is still not known. The neutrophil granulocyte plays an important part in the inflammatory process-for example, in rheumatoid arthritis, and the effect of auranofm on neutrophil function has been studied by several investigators. Auranofm has been shown to inhibit phagocytosis,1 2 chemotaxis,2 release of lysosomal enzymes,' 2the respiratory burst, and the generation of leukotrienes3 in neutrophils. In most of these studies the effect of auranofm was investigated on neutrophil functions stimulated with the chemotactic peptide N-formylmethionyl-leucyl-phenylalanine (fMLP) the complement factor CSA, or a non-physiological stimulus such as phorbol ester or calcium ionophore. Cytokines can activate neutrophils,4 5 and a pathogenetic role for cytokines in rheumatoid arthritis has been proposed. 6 Tumour necrosis factor was detected in synovial tissues from patients with rheumatoid arthritis, but not in controls.7 Moreover, this factor has been found in synovial fluid and serum from patients with rheumatoid arthritis.8 A role for granulocyte-macrophage colony stimulating factor (GM-CSF) in rheumatoid synovitis has also been suggested.9 Considering these findings we decided to investigate whether auranofm could affect the tumour necrosis factor and GM-CSF mediated effects on neutrophils. By using a haemolytic plaque assay to detect degranulation from single adherent neutrophils we have previously shown that both these cytokines induce secretion of granule proteins such as lactoferrin and myeloperoxidase.' In this study the plaque assay was used to investigate the effect of auranofm on degranulation of adherent neutrophils induced by tumour necrosis factor and GM-CSF and to compare it with the effect on secretion mediated by fMLP, phorbol diester, and calcium ionophore. Protein A (Pharmacia, Sweden) was coupled to sheep's red blood cells as previously described. 2 In short, these cells, stored in Alsever's solution and aged one to three weeks, were washed three times in 0-15 M NaCl. One part packed sheep's red blood cells was mixed with one part protein A (0-5 mg/ml in 0-15 M NaCl) and 10 addition of 1 ml of a 1% suspension of protein A-sheep's red blood cells in HBSS. After 15 minutes' incubation at 4°C surplus protein Asheep's red blood cells was poured off, followed by addition of antilactoferrin (1/2560) or antimyeloperoxidase (1/320) and guinea pig complement (1/100, Flow Laboratories), granulocytes, and a stimulatory agent dissolved in 1 ml of HBSS. About 330 granulocytes were added to each dish. The dishes were incubated for two hours at 37°C and then fixed with a 5% solution of glutaraldehyde in phosphate buffer and stored at 4°C until the haemolytic plaques were counted under a microscope. A plaque was defined as a round area in which all the sheep's red blood cells had been lysed. In questionable cases a higher magnification was used to identify the single granule protein secreting neutrophil in the middle of the haemolytic zone before a plaque was actually defined as a plaque.
Results

EFFECT OF AURANOFIN ON LACTOFERRIN SECRETION
Neutrophils (106/ml in HBSS with 1% fetal bovine serum) were incubated at 37°C for five minutes with various concentrations of auranofin, then added to the plaque assay system with the same concentration of auranofin and exposed to either tumour necrosis factor (1 nmolll), GM-CSF (1 nmol/l), fMLP (100 nmol/l), A23187 (1 Wimoll1), phorbol myristate acetate (10 ng/ml), or no stimulus. Figure 1 shows the results obtained. At low concentrations (0-251-0 ,ig/ml) auranofin enhanced lactoferrin plaque formation in response to fMLP and GM-CSF. At higher concentrations (20A4-0 Fg/ml), however, an inhibitory effect of auranofm was seen. Lactoferrin secretion induced by tumour necrosis factor, on the other hand, was not enhanced by auranofin, and an inhibitory effect was noted even at 0-25 [ig/ml. tDoes not take into account the peak seen at 2 sg/ml (fig 3) . Auranofin (jg/ml) Figure 3 Effect ofauranofin on myeloperoxidase (MPO) secretion from adherent neutrophils. Neutrophils (106/ml in Hanks's balanced salt solution with 1% fetal bovine serum)
were incubated at 37°Cforfive minutes with the indicated concentrations ofauranofin and then added to the plaque assay system wtth the same concentration ofauranofin and cytochalasinB (0-3 Ig/ml). Subsequenly, the cells were exposed to 10 nM tumour necrosis factor(A-A ), 100 nM N-formyl-methionYl-kucYl-phenylalanine (-U) 10 
Discussion
Adherence of neutrophils to a surface has been suggested to play an important part in activation of these cells by cytokines,'3 14 which makes the plaque assay suitable for studying the effects of cytokines on neutrophil degranulation. It should be noted that the haemolytic plaque assay is semiquantative as it measures the fraction of adherent neutrophils undergoing exocytosis but not the amount of protein secreted. On the other hand, the assay makes it possible to study secretion at the single cell level and only a limited number of cells is required.
The effect of auranofm on release of granule proteins from neutrophils has been investigated before.2 A biphasic response was described for fMLP induced secretion of lysozyme (a protein found in both primary and secondary granules) and f3-glucuronidase (solely located in primary granules). These results are well in accordance with our findings of enhancement of both lactoferrin and myeloperoxidase secretion at low but inhibition at higher concentrations of auranofin. In the previous work auranofin was found not to affect enzyme release in response to calcium ionophore in the concentration range 1-4 g/mI.2 This also correlates closely with our observation that significant inhibition of exocytosis mediated by calcium ionophore only occurred at high concentrations of auranofm.
The effect of auranofin on neutrophil functions activated by cytokines has, to our knowledge, not been investigated previously. Our findings of inhibitory effects of auranofm, particularly on tumour necrosis factor induced, but also GM-CSF induced degranulation at low concentrations are of clinical interest but may also help to explain the signal-transduction mechanisms taking place. The serum concentrations of auranofin obtained after long term oral administration of the drug are in the approximate rate 15-3-5 P/mI.2 Enzyme release in response to fMLP, phorbol myristate acetate, or A23187 is not significantly inhibited within this concentration range (present data),2 whereas degranulation induced both by tumour necrosis factor and GM-CSF is inhibited by more than 50%. In view of this, and the proposed role of cytokines in rheumatoid arthritis,6 it might be more relevant to investigate the effect of auranofm on neutrophils incubated with cytokines as compared with phorbol esters, ionophores, and even fMLP in order to understand how auranofm affects the inflammatory process in rheumatoid arthritis.
The biphasic response to auranofm was also noted in the kinetic experiments performed. Preincubation of neutrophils with auranofm for one to three minutes before addition of one of the receptor mediated agonists tumour necrosis factor, GM-CSF, or fMLP enhanced the secretory response, whereas preincubation for 10-20 minutes resulted in an inhibition of degranulation. In a previous study the inhibitory effect was found to be almost complete after five minutes,'5 but the experiments were carried out in medium devoid of serum or albumin. Cells take up auranofm more slowly in the presence of serum'6 and this might account for the longer preincubation time for the inhibitory effect to occur found in our study, in which cells were incubated with auranofm in the presence of 1% fetal bovine serum.
The exact mode of action of auranofm at the cellular level is not understood. It has been suggested that the effect on neutrophils is mediated through inhibition of protein kinase C.'7 At a concentration of 20 iimol/l (13-6 ,tg/ml) auranofin was reported to inhibit superoxide production and translocation of protein kinase C from the cytosol to the plasma membrane in response to phorbol myristate acetate, an activator of protein kinase C. In the present study auranofin at a concentration of at least 10 [ig/ml was required to show an effect on degranulation induced by phorbol myristate acetate. A concentration of less than 1 [tg/ml was needed to inhibit substantially lactoferrin secretion induced by tumour necrosis factor. Therefore, it is unlikely that protein kinase C is the point of action for auranofm for degranulation in neutrophils mediated by tumour necrosis factor. This is further supported by the fact that so far no involvement of protein kinase C in tumour necrosis factor signal-transduction in neutrophils has been shown.'8 Thus at clinical concentrations of auranofm it is more likely that the action is exerted at some other point in the signal-transduction process. The finding that auranofin at the same dose enhanced lactoferrin secretion induced by GM-CSF and inhibited that induced by tumour necrosis factor indicates that the two cytokines exert their effects through distinct signaltransduction pathways.
In conclusion, we have found that auranofin inhibits tumour necrosis factor and GM-CSF induced granule protein secretion from adherent human neutrophils at concentrations that are close to those seen in the serum of patients treated with auranofm. In the light of the proposed role of cytokines in rheumatoid arthritis this finding may help to explain the clinical effects of auranofm.
The sheep red blood cells were kindly supplied by the department of microbiology, University of Lund, Sweden.
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